1. Home
  2. ZYME vs CRESY Comparison

ZYME vs CRESY Comparison

Compare ZYME & CRESY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • CRESY
  • Stock Information
  • Founded
  • ZYME 2003
  • CRESY 1936
  • Country
  • ZYME United States
  • CRESY Argentina
  • Employees
  • ZYME 290
  • CRESY N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • CRESY Real Estate
  • Sector
  • ZYME Health Care
  • CRESY Finance
  • Exchange
  • ZYME Nasdaq
  • CRESY Nasdaq
  • Market Cap
  • ZYME 956.0M
  • CRESY 815.5M
  • IPO Year
  • ZYME 2017
  • CRESY 1997
  • Fundamental
  • Price
  • ZYME $13.88
  • CRESY $12.09
  • Analyst Decision
  • ZYME Buy
  • CRESY
  • Analyst Count
  • ZYME 6
  • CRESY 0
  • Target Price
  • ZYME $19.17
  • CRESY N/A
  • AVG Volume (30 Days)
  • ZYME 565.8K
  • CRESY 235.0K
  • Earning Date
  • ZYME 03-05-2025
  • CRESY 02-07-2025
  • Dividend Yield
  • ZYME N/A
  • CRESY 8.21%
  • EPS Growth
  • ZYME N/A
  • CRESY N/A
  • EPS
  • ZYME N/A
  • CRESY N/A
  • Revenue
  • ZYME $62,199,000.00
  • CRESY $751,941,316.00
  • Revenue This Year
  • ZYME $21.53
  • CRESY N/A
  • Revenue Next Year
  • ZYME N/A
  • CRESY N/A
  • P/E Ratio
  • ZYME N/A
  • CRESY N/A
  • Revenue Growth
  • ZYME N/A
  • CRESY N/A
  • 52 Week Low
  • ZYME $7.97
  • CRESY $6.56
  • 52 Week High
  • ZYME $17.70
  • CRESY $14.23
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 48.04
  • CRESY 41.82
  • Support Level
  • ZYME $12.80
  • CRESY $12.64
  • Resistance Level
  • ZYME $14.63
  • CRESY $14.03
  • Average True Range (ATR)
  • ZYME 0.85
  • CRESY 0.74
  • MACD
  • ZYME -0.04
  • CRESY -0.16
  • Stochastic Oscillator
  • ZYME 25.29
  • CRESY 9.09

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About CRESY Cresud S.A.C.I.F. y A.

Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.

Share on Social Networks: